. 2013 Aug 22;2013:740615. doi: 10.1155/2013/740615

Table 2.

Relapsed/refractory immunochemotherapy for CLL patients.

Trial	Regiments	N	CR	OR	OS (months)	Median PFS (months)
Robak et al. [25]	RC	18	13%	67%	ND	12
Robak et al. [25]	versus RCC	28	9%	78%	ND	12
Robak et al. [26]	FC	276	13%	58%	46	20.6
Robak et al. [26]	versus RFC	276	24.3%	69.6%	64	30.6
Castro et al. [27]	Rituximab HDMP	14	36%	93%	ND	ND
Wierda [28]	Ofatumumab, FA-ref,	95	0%	51%	14.2	5.5
Wierda [28]	versus ofatumumab, BF-ref	111	2%	54%	17.4	5.5
Gritti et al. [29]	Alemtuzumab	18	8%	44%	ND	14.6
Zent et al. [30]	PAR	19	32%	74%	23	7
Badoux et al. [31]	CFAR	31	29%	65%	11	7
O'Brien et al. [32]	FC	120	9%	17%	34	6
O'Brien et al. [32]	versus FC-oblimersen	121	3%	7%	33	9
Chen et al. [33]	Lenalidomide	25	0%	56%	24	24

N: number of patients in the trial, CR: complete response, OR: overall response, OS: overall survival, PFS: progression-free survival, ND: no data, FC: fludarabine and cyclophosphamide, RFC: rituximab, fludarabine, and cyclophosphamide, RC: rituximab, cladribine and RCC: rituximab, cladribine, and cyclophosphamide, PAR: pentostatin, alemtuzumab, and rituximab, CFAR: cyclophosphomide, fludarabine, alemtuzumab, and rituximab, HDMP: high-dose methylprednisolone, BF-ref: fludarabine refractory, FA-ref: fludarabine and alemtuzumab refractory.